Prognostic factor of anti-MDA-5 antibody positive dermatomyositis

Prognostic factor of anti-MDA-5 antibody positive dermatomyositis - Prognostic factor of anti-MDA-5 antibody positive dermatomyositis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000046900

Enrollment

Registered

2022-03-01

Start date

2022-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anti-MDA5 antibody positive dermatomyositis

Interventions

serum KL-6, CRP, LDH, ferritin level at every week for 3 months. Evaluate the outcome at 6 months later. vital signs at every week for 3 months. Evaluate the outcome at 6 months later.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: This study included 85 consecutive patients diagnosed with PM/DM between 2002 and 2020 at the Kurume University Hospital. Clinical data, cumulative disease manifestations, laboratory investigations, associated diseases, therapy, clinical course, disease complications, and outcomes were retrospectively recorded from medical records.

Exclusion criteria

Exclusion criteria: Patients who were not agree with our research were excluded.

Design outcomes

Primary

Measure	Time frame
outcome after 6 months from initial treatment	—

Countries

Japan

Contacts

Public ContactMasaki Tominaga

Kurume University School of Medicine 8300011

tominaga_masaki@med.kurume-u.ac.jp+81942317586

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026